CytomX Therapeutics, Inc.

United States

Website: http://cytomx.com/

Show jobs for this employer

227 articles about CytomX Therapeutics, Inc.

  • CytomX Therapeutics, Inc. announced that on September 15, 2021, the Company granted nine new employees options to purchase a total of 157,200 shares of the Company’s common stock at an exercise price per share equal to $4.97, which was the closing trading price on September 15, 2021, the date of the grant.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference.

  • CytomX Therapeutics, Inc. announced that on August 16, 2021, the Company granted seven new employees options to purchase a total of 172,600 shares of the Company’s common stock at an exercise price per share equal to $4.81, which was the closing trading price on August 16, 2021, the date of the grant.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today reported second quarter 2021 financial results and provided a business update.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

  • CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the close of U.S. markets.

  • CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, announced that results from its Phase 1 first-in-human study of CX-2029 in patients with advanced solid tumors were published online in the peer-reviewed journal Clinical Cancer Research.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that Amy Peterson, M.D., chief development officer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference

  • CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, reported first quarter 2021 financial results and provided a business update.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that it will report first quarter 2021 financial results on Thursday, May 6, 2021,

  • CytomX Therapeutics, Inc. announced that on April 1, 2021, the Company granted a new employee an option to purchase a total of 120,000 shares of the Company’s common stock at an exercise price per share equal to $7.87, which was the closing trading price on April 1, 2021, the date of the grant.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that it will host a virtual investor event at 1:00 p.m. – 3:00 p.m. ET / 10:00 a.m. – 12:00 p.m.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today reported fourth quarter and full year 2020 financial results and provided a business update.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in March. Cowen 41 st Annual Virtual Health Care Conference

  • CytomX Therapeutics, Inc. announced that on February 15, 2021, the Company granted a new employee an option to purchase a total of 65,000 shares of the Company’s common stock at an exercise price per share equal to $8.64, which was the closing trading price on February 16, 2021, the date of the grant.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform, today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after the close of U.S. markets.

  • CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11th at 3:30 p.m. ET.

  • CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an additional 2,142,857 shares of common stock, pursuant to the exercise in full of the underwriters’ option to purchase additional shares

  • CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an additional 2,142,857 shares of common stock, pursuant to the exercise in full of the underwriters’ option to purchase additional shares in connection with CytomX’s previously announced underwritten public offering of common stock.